Should You Buy OHB Pediatrics Before the SPAC Merger Closes?
OHB Pediatrics Ltd. d/b/a Oak Hill Bio is a clinical-stage rare-disease therapeutics company going public through a merger with Research Alliance Corp III (Nasdaq: RACC). The deal is valued at about $160 million in base equity value, plus outstanding SAFEs and accrued interest, but the cash that actually reaches the company will depend on redemptions and committed financing.
OHB Pediatrics Ltd. d/b/a Oak Hill Bio is a clinical-stage rare-disease therapeutics company going public through a merger with Research Alliance Corp III (Nasdaq: RACC). The deal is valued at about $160 million in base equity value, plus outstanding SAFEs and accrued interest, but the cash that actually reaches the company will depend on redemptions and committed financing.
Deal at a Glance
SPAC partner: Research Alliance Corp III
SPAC ticker (trades now): RACC
Implied valuation: $160M base equity value
Expected close: late Q3 2026 to Q4 2026
Est. first trading date: late Q3 2026 to Q4 2026
Deal status: Announced
Source filing: SEC 425 (2026-07-28)
Company Overview
OHB Pediatrics Ltd. d/b/a Oak Hill Bio is a clinical-stage rare-disease therapeutics company incorporated in England and Wales. The company’s lead program appears to be OHB-607, a therapy being studied for prevention of bronchopulmonary dysplasia in extremely premature infants and preterm neonates. Public materials identify the company as a biotechnology R&D business rather than a commercial-stage drug maker.
That matters because the story is still about pipeline value, not current sales. The company was incorporated on September 16, 2024, and the accessible materials do not disclose a product portfolio, revenue base, or operating history beyond its clinical-stage development work. The broader backdrop is attractive on paper: rare diseases affect more than 30 million people in the U.S., about half of them children, and the FDA highlights orphan-drug and rare-pediatric-disease incentives.
The SPAC Deal
OHB Pediatrics is merging with Research Alliance Corp III, a healthcare-focused SPAC that currently trades as RACC. The transaction was announced on July 27, 2026, and the company said it entered into a definitive business combination agreement. The clearest valuation figure disclosed in the accessible materials is an approximately $160 million base equity value, plus outstanding SAFEs and accrued interest. The S-4/proxy was not available in the sources I could access, so a full pro forma enterprise value and the final dilution stack are not yet disclosed.
On the financing side, Research Alliance Corp III’s IPO raised $75.0 million gross and deposited $75.0 million into trust. That is the trust pool the deal is drawing from, so redemption risk is real: if shareholders redeem heavily, the cash delivered at close could be materially lower. The materials also show a subscription agreement and a backstop agreement with RA Capital Healthcare Fund, L.P., but the exact committed amount was not visible in the accessible excerpts. Sponsor equity exists as well: the sponsor bought 275,000 Class A ordinary shares at $10.00 for $2.75 million, which adds dilution. I could not verify the public warrant terms or a post-close warrant overhang table from the accessible filings.
The current SPAC ticker is RACC, and the expected post-merger ticker was not disclosed in the materials I could verify. Based on the announcement timing and the fact that the deal is still only announced, the first trading window is most likely late Q3 to Q4 2026 if the vote, SEC review, and closing all proceed on a normal SPAC timetable.
Get AI research on any stock
Instant reports, daily intelligence, and an AI analyst in your pocket.
For OHB Pediatrics, the SPAC route is a faster path to public capital than a traditional IPO and can be more flexible for a clinical-stage biotech that does not yet have commercial revenue. The merger structure can also help the company tell a pipeline story around OHB-607 while accessing public-market funding for development, regulatory work, and trial execution.
The deal also comes with sponsor backing and committed financing support from RA Capital Healthcare Fund, L.P., which can help bridge the gap between the trust account and the capital the company wants at close. That said, the accessible materials do not disclose a PIPE size, so shareholders should watch how much additional capital is actually locked in versus how much depends on the redemption outcome.
Financial Highlights
The accessible materials do not disclose OHB Pediatrics revenue, growth, margins, or a cash balance. That is consistent with a clinical-stage company: the value proposition is tied to OHB-607 and its development path, not to an existing commercial business. The only concrete development-stage detail I could verify is that OHB-607 is in Phase 2b development for BPD prevention in preterm neonates.
Because the company is not yet commercial, there is no disclosed operating runway in the materials I could access. Any post-close runway discussion will depend on the final cash delivered from trust, the backstop/subscription financing, and how much capital the company raises or preserves after redemptions and transaction costs. Any forward-looking operating figures would be projections, and those were not available in the accessible sources.
Risk Factors
The biggest risk is clinical execution. OHB Pediatrics is still a clinical-stage biotech, and OHB-607 has to prove itself in a difficult neonatal setting before the market can underwrite a durable commercial story. Regulatory risk is high as well: pediatric rare-disease drug development is heavily scrutinized and outcome-dependent.
The de-SPAC risks are just as important. The SPAC trust is $75 million, so redemptions could drain the cash available at close. Sponsor equity and any additional financing create dilution, and the exact warrant overhang was not disclosed in the accessible materials. There is also deal-completion risk: the transaction is announced and definitive, but not yet closed, and the final vote, SEC effectiveness, and closing timeline were not disclosed in the materials I could verify.
Comparable Public Companies
The closest public comps are rare-disease biotech names rather than pediatric-only companies. A reasonable peer set includes BridgeBio Pharma (BBIO), Ultragenyx Pharmaceutical (RARE), Sarepta Therapeutics (SRPT), PTC Therapeutics (PTCT), and BioMarin Pharmaceutical (BMRN). These names are the right framework because OHB Pediatrics is being valued as a development-stage rare-disease platform, not as a revenue compounder.
I did not pull live trading multiples from market data, so I am not assigning current EV/revenue or EV/peak-sales ranges here. Directionally, this peer group tends to trade on pipeline quality, clinical catalysts, and regulatory optionality rather than near-term earnings. For OHB Pediatrics, the market will likely focus on whether the $160 million base equity value looks cheap or rich relative to the stage of OHB-607 and the amount of cash that survives the SPAC process.
Like what you're reading?
Get full access to AI-powered research reports, market analysis, and portfolio tools.
The setup is straightforward: this is a clinical-stage rare-disease de-SPAC with a real pipeline story, but the deal economics are still incomplete. Shareholders should watch the final S-4/proxy for the PIPE/backstop size, redemption levels, warrant terms, and the actual cash that lands on the balance sheet at close.
Why this matters now is that the market is being asked to price OHB Pediatrics before the full dilution picture is visible. The base equity value is about $160 million, but the post-close outcome will depend on how much trust cash remains after redemptions and how much sponsor and financing dilution gets layered in. If the company can preserve cash and keep the financing stack tight, the story has upside optionality; if not, the deal may leave the public float with less capital than the headline valuation suggests.
▌The Daily Briefing · Free
A new stock idea, every evening.
One stock worth watching each weekday, plus the analysis behind it. Free, in your inbox.
